But the story doesnt end with gut health
Current Texas Medicaid guidelines generally require: A confirmed diagnosis of type 2 diabetes Prior authorization BMI documentation Evidence that other treatments have been attempted In most cases, weight-loss-only indications are not covered under Texas Medicaid
I noticed a significant difference in my hunger levels as well as my energy levels
New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound
Glucagon-like peptide-1 (GLP-1) is a weekly injectable medication that stimulates insulin release, slows gastric motility, reduces appetite, and stabilizes blood sugar
[31] The takeaway is vigilance: any GLP-1 user with diabetes especially on combined therapy with SGLT2 inhibitors, who presents with persistent vomiting or reduced oral intake deserves consideration for EDKA
)
